AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has provided an update to investors regarding the status of Leon Wang, Executive Vice President International and AstraZeneca China President. The company has confirmed that Wang is currently “in detention” in China and was last reported to be “cooperating with the investigation” on the evening of October 30th.
Company Overhaul and Leadership Change
Public information reveals that AstraZeneca has undergone significant changes, reflecting a major overhaul within the company. The leadership has transitioned from Leon Wang to MAQDOSI EWA (Meng Yihua), marking a shift in the executive management. This change comes amidst the ongoing investigation involving Wang and the company’s restructuring efforts.
Market Entity Type and Investor Changes
The market entity type of AstraZeneca has been altered from “limited liability company (Sino foreign cooperation)” to “limited liability company (sole proprietorship of foreign legal person)”. This change signifies a transformation in the company’s legal and operational structure. Investors have also seen a shift, with Wuxi Xinfa Group Co., Ltd., Jiangsu Wuxi Medical and Pharmaceutical Co., Ltd., and AstraZeneca Continent B.V. being replaced by AstraZeneca Continent B.V. as the sole proprietor, indicating the exit of the Chinese investment entity from the partnership.-Fineline Info & Tech
Leave a Reply